Please login to the form below
HER2-negative breast cancer
This page shows the latest HER2-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca's Lynparza recommended by NICE for breast and prostate cancer
The anti-cancer medicine will now be routinely available for adults with HER2-negative, high-risk early breast cancer who have inherited faults in their BRCA1 or BRCA2 genes, after surgery ... NICE estimates that 300 adults with breast cancer will now be
Latest news
-
Eli Lilly’s Verzenio label expanded by FDA for early breast cancer patients
The decision to remove the previous 20% Ki-67 score requirement for patient selection means that those with HR-positive, HER2-negative early breast cancer can now be identified solely based ... Although the prognosis for HR-positive, HER2-negative early
-
Gilead’s Trodelvy approved by FDA for metastatic breast cancer
The authorisation is specifically for adult patients with unresectable locally advanced or metastatic HR-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two ... for people with metastatic
-
Gilead’s Trodelvy granted FDA priority review for metastatic breast cancer
Gilead’s supplemental Biologics Licence Application for Trodelvy (sacituzumab govitecan-hziy) for pre-treated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer patients has ... HR+/HER2-
-
AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer
Food and Drug Administration (FDA) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), AZ announced. ... The announcement follows the European Commission’s approval of Lynparza earlier this month for the
-
Gilead Sciences announce positive results for Trodelvy in breast cancer patients
HR+/HER2- breast cancer accounts for around 70% of all new cases, or nearly 400, 000 diagnoses worldwide each year. ... HR+/HER2- breast cancer is the most common type of breast cancer, accounting for around 70% of all new cases, or nearly 400, 000
More from news
Approximately 1 fully matching, plus 86 partially matching documents found.
Latest Intelligence
-
Leading AstraZeneca’s return to growth in Europe
The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in
-
The handover: Pfizer reshapes itself for a new era
Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
